Mckesson Corp (MCK)
Fair ValueFundamental
78
Price
$1000.77
Market Cap
$118.40B
Part 1 · What the company is worth
Overview
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 19, 2026, shared with all users
McKesson's 10-K names Cencora as one of its two largest competitors: both are national full-line wholesalers distributing branded, generic and specialty drugs to the same U.S. pharmacy chains, health systems and physician practices.
The other of the two competitors McKesson names by name: Cardinal Health bids for the same U.S. drug-distribution contracts and also sells medical-surgical supplies to the same hospitals and surgery centers.
Henry Schein's own 10-K names McKesson as one of its two primary national competitors in the medical market, where both supply consumables and equipment to office-based physicians and dental practices.
Privately held national distributor of medical-surgical supplies, competing head-on with McKesson Medical-Surgical for hospital, surgery-centre and physician-office supply contracts.
Distributor of medical-surgical products to U.S. acute-care hospitals and health systems, bidding for the same supply-chain contracts as McKesson's Medical-Surgical Solutions segment.
Privately held regional full-line pharmaceutical wholesaler in the U.S. South, serving the independent pharmacies and regional hospital groups that McKesson also supplies.
Balance Sheet & Liquidity
Revenue
$410.98B
Trailing 12 months (through 6/30/2026)
Net Income
$4.59B
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$5.72B
Total Equity
$-2.17B
Total Liabilities
$84.10B
Current Ratio
0.89
Interest Coverage
23.62
Debt/EBITDA
1.80
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$921.32
Current Price
$1000.77
Margin of Safety
-8.6%
Fair Value Range
$669.97 - $1172.66
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
26.84
ROE
-219.2%
P/B Ratio
-
P/FCF
18.19
Gross Margin
3.6%
ROIC
28.5%
Profitability Radar
Value Creation (Economic Moat)
ROIC
28.5%
WACC
7.4%
ROIC − WACC
+21.1 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- EPS CAGR 14.57%
- Price CAGR 21.40%
- ROIC 28.5%
- P/FCF 18.19
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- ROE 39.4%
- Revenue growth 5Y 11.1%
- Earnings quality (operating cash flow / net income) 1.49
- Share dilution -3.1%
- Net margin trend 1.1% vs 0.8%
- Piotroski F-Score 7/9
Failed (5)
- Gross margin 3.6%
- Operating margin 1.6%
- Low reliance on intangibles
- DCF valuation (Overvalued)
- Earnings surprise, average 2.1%
Unavailable (5)
- P/B ratio –
- Dividend payout –
- Debt/equity ratio
- Price below Graham Number
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Chairman | 58 |
| Ms. Michele Lau J.D. | Executive VP & Chief Legal Officer | 49 |
| Ms. LeAnn B. Smith | Executive VP & Chief Human Resources Officer | 50 |
| Mr. Kenny K. Cheung | Executive VP & CFO | 43 |
| Mr. Napoleon B. Rutledge Jr. | Senior VP, Controller & Chief Accounting Officer | 52 |
| Paula Adkison | Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance | - |
| Mr. Francisco J. Fraga | Executive VP, Chief Information Officer & CTO | 52 |
| Ms. Jeni Dominguez | Head of Investor Relations | - |
| Mr. Kirk Kaminsky | Executive VP & Group President of North American Pharmaceutical Services | - |
| Mr. Stanton J. McComb | President of Medical-Surgical | - |
Audit Risk
10
Board Risk
6
Compensation Risk
1
Shareholder Rights Risk
4
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much MCK moves, measured on its daily prices.
More volatile than 35% of the tracked stocks (90-day volatility).
- Volatility 30d
- 25.4%
- Volatility 90d
- 30.1%
- Beta vs S&P 500 (1y)
- -0.26Correlation -0.11
- Max drawdown (12m)
- -27.2%
- ATR (14d, % of price)
- 2.24%
Earnings reactions
How MCK moved around its past quarterly results.
Next earnings release
Nov 4, 2026 · In 11 days · Time not known
EPS estimate: 10.75Revenue estimate: $110.0B
What usually happens
- Over the last 12 releases the stock moved a median of 2.5% the next day, up or down.
- Next-day moves: up 4, down 8 (out of 12).
- Of the 5 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | After the close | 9.63 | 9.93 | +3.1% | +4.0% | -0.7% | +0.2% |
| May 7, 2026 | After the close | 11.68 | 11.69 | +0.1% | -2.0% | -2.5% | -1.0% |
| Feb 4, 2026 | After the close | 9.31 | 9.34 | +0.3% | +4.9% | +16.5% | +16.0% |
| Nov 5, 2025 | After the close | 9.13 | 9.86 | +8.0% | -1.4% | +1.7% | -0.4% |
| Aug 6, 2025 | After the close | n/a | n/a | n/a | -2.9% | -5.8% | -5.8% |
| May 8, 2025 | After the close | 9.92 | 10.12 | +2.0% | +3.2% | +0.5% | +2.4% |
| Feb 5, 2025 | After the close | n/a | n/a | n/a | -2.8% | -1.2% | -2.0% |
| Nov 6, 2024 | After the close | n/a | n/a | n/a | +10.4% | +10.6% | +13.7% |
| Aug 7, 2024 | After the close | n/a | n/a | n/a | -7.1% | -11.3% | -10.5% |
| May 7, 2024 | After the close | n/a | n/a | n/a | +1.2% | -0.4% | +1.1% |
| Feb 7, 2024 | After the close | n/a | n/a | n/a | -2.3% | -4.4% | -3.1% |
| Nov 1, 2023 | After the close | n/a | n/a | n/a | -4.0% | -2.6% | +0.2% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on MCK and what the price did next.
- 4/8/2026PositiveHere's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
- +1 day
- -0.3%
- +3 days
- -2.3%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for MCK.
- 6/3/2026NEUTRALMcKesson Unit Prices $2.25 Billion Leveraged Loan Ahead of IPO
McKesson Corp.'s medical-surgical unit has priced a $2.25 billion leveraged loan. This move precedes the unit's anticipated initial public offering (IPO). While the loan issuance itself is a financing activity, its direct impact on McKesson's stock price is neutral at this stage. The successful pricing indicates market appetite for the unit's debt, which could be a positive precursor to the IPO, but the primary focus remains on the upcoming equity offering rather than the debt itself for immediate trading signals.
- 4/8/2026POSITIVEHere's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
An investment of $100 in McKesson Corporation (MCK) twenty years ago would have grown to approximately $1,640 today, representing a significant 16.4x return. This performance indicates a strong compound annual growth rate (CAGR) over the past two decades, outperforming many market benchmarks. The sustained growth suggests effective business strategy, operational efficiency, and favorable market positioning within the healthcare distribution sector. For investors, this historical data highlights McKesson's long-term value creation potential and its resilience through various economic cycles.